S&P 500   4,259.20 (-0.34%)
DOW   33,450.77 (-0.50%)
QQQ   352.16 (-0.58%)
AAPL   169.54 (-1.41%)
MSFT   310.37 (-0.57%)
META   289.95 (-3.01%)
GOOGL   129.07 (+0.39%)
AMZN   125.06 (-0.73%)
TSLA   236.46 (-3.14%)
NVDA   418.57 (-0.13%)
NIO   8.40 (-0.12%)
BABA   85.66 (-0.29%)
AMD   97.18 (+1.27%)
T   14.84 (-1.20%)
F   12.29 (-1.13%)
MU   67.07 (-1.28%)
CGC   0.91 (-1.69%)
GE   110.33 (+0.36%)
DIS   79.48 (-0.71%)
AMC   7.64 (-3.41%)
PFE   32.06 (-1.05%)
PYPL   56.81 (-3.60%)
NFLX   376.85 (-0.63%)
S&P 500   4,259.20 (-0.34%)
DOW   33,450.77 (-0.50%)
QQQ   352.16 (-0.58%)
AAPL   169.54 (-1.41%)
MSFT   310.37 (-0.57%)
META   289.95 (-3.01%)
GOOGL   129.07 (+0.39%)
AMZN   125.06 (-0.73%)
TSLA   236.46 (-3.14%)
NVDA   418.57 (-0.13%)
NIO   8.40 (-0.12%)
BABA   85.66 (-0.29%)
AMD   97.18 (+1.27%)
T   14.84 (-1.20%)
F   12.29 (-1.13%)
MU   67.07 (-1.28%)
CGC   0.91 (-1.69%)
GE   110.33 (+0.36%)
DIS   79.48 (-0.71%)
AMC   7.64 (-3.41%)
PFE   32.06 (-1.05%)
PYPL   56.81 (-3.60%)
NFLX   376.85 (-0.63%)
S&P 500   4,259.20 (-0.34%)
DOW   33,450.77 (-0.50%)
QQQ   352.16 (-0.58%)
AAPL   169.54 (-1.41%)
MSFT   310.37 (-0.57%)
META   289.95 (-3.01%)
GOOGL   129.07 (+0.39%)
AMZN   125.06 (-0.73%)
TSLA   236.46 (-3.14%)
NVDA   418.57 (-0.13%)
NIO   8.40 (-0.12%)
BABA   85.66 (-0.29%)
AMD   97.18 (+1.27%)
T   14.84 (-1.20%)
F   12.29 (-1.13%)
MU   67.07 (-1.28%)
CGC   0.91 (-1.69%)
GE   110.33 (+0.36%)
DIS   79.48 (-0.71%)
AMC   7.64 (-3.41%)
PFE   32.06 (-1.05%)
PYPL   56.81 (-3.60%)
NFLX   376.85 (-0.63%)
S&P 500   4,259.20 (-0.34%)
DOW   33,450.77 (-0.50%)
QQQ   352.16 (-0.58%)
AAPL   169.54 (-1.41%)
MSFT   310.37 (-0.57%)
META   289.95 (-3.01%)
GOOGL   129.07 (+0.39%)
AMZN   125.06 (-0.73%)
TSLA   236.46 (-3.14%)
NVDA   418.57 (-0.13%)
NIO   8.40 (-0.12%)
BABA   85.66 (-0.29%)
AMD   97.18 (+1.27%)
T   14.84 (-1.20%)
F   12.29 (-1.13%)
MU   67.07 (-1.28%)
CGC   0.91 (-1.69%)
GE   110.33 (+0.36%)
DIS   79.48 (-0.71%)
AMC   7.64 (-3.41%)
PFE   32.06 (-1.05%)
PYPL   56.81 (-3.60%)
NFLX   376.85 (-0.63%)
NASDAQ:MESO

Mesoblast (MESO) Price Target & Analyst Ratings

$1.26
+0.03 (+2.44%)
(As of 01:49 PM ET)
Compare
Today's Range
$1.24
▼
$1.29
50-Day Range
$1.22
▼
$4.83
52-Week Range
$1.16
▼
$5.12
Volume
83,017 shs
Average Volume
280,402 shs
Market Capitalization
$205.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.13
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Mesoblast Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 6 Analyst Ratings

Consensus Analyst Price Target

$7.13
465.48% Upside
High Prediction$17.00
Average Prediction$7.13
Low Prediction$1.50
TypeCurrent
9/27/22 to 9/27/23		1 Month Ago
8/28/22 to 8/28/23		3 Months Ago
6/29/22 to 6/29/23		1 Year Ago
9/27/21 to 9/27/22
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
1 Buy rating(s)
Hold
3 Hold rating(s)
4 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$7.13$8.63$10.00$4.75
Predicted Upside465.48% Upside129.48% Upside198.73% Upside49.84% Upside
Get Mesoblast Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.


MESO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MESO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Mesoblast Stock vs. The Competition

TypeMesoblastMedical CompaniesS&P 500
Consensus Rating Score
2.17
2.66
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside479.27% Upside1,373.88% Upside697.64% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/21/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweight ➝ Overweight$17.00+1,197.70%
8/31/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy
8/7/2023Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold
8/4/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetSell ➝ Sell$2.00 ➝ $1.50-62.41%
8/4/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOverweight ➝ Neutral$7.00 ➝ $2.00-49.87%
8/4/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating		S. Corwin
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Market Perform
(Data available from 9/27/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












MESO Price Target - Frequently Asked Questions

What is Mesoblast's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for Mesoblast stock is Hold based on the current 1 sell rating, 3 hold ratings and 2 buy ratings for MESO. The average twelve-month price prediction for Mesoblast is $7.13 with a high price target of $17.00 and a low price target of $1.50. Learn more on MESO's analyst rating history.

Do Wall Street analysts like Mesoblast more than its competitors?

Analysts like Mesoblast less than other Medical companies. The consensus rating for Mesoblast is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how MESO compares to other companies.

Is Mesoblast being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, Mesoblast's stock had 3 downgrades and 1 upgrade by analysts.

Does Mesoblast's stock price have much upside?

According to analysts, Mesoblast's stock has a predicted upside of 123.35% based on their 12-month price targets.

What analysts cover Mesoblast?

Mesoblast has been rated by Cantor Fitzgerald, Chardan Capital, Jefferies Financial Group, Maxim Group, Piper Sandler, and William Blair in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:MESO) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -